Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06243276
Other study ID # EUDF-OKUMUS-002
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 5, 2024
Est. completion date May 14, 2025

Study information

Verified date May 2024
Source Erzincan University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to compare one- and two-stage techniques for short implant surgery in diabetes. The main questions it aims to answer are: - Is one-stage short implant surgery at risk of implant osseointegration in diabetic patients compared to two-stage surgery? - Is one-stage short implant surgery associated with a risk of implant survival (at one-year follow-up) in diabetic patients compared to two-stage surgery? - What are the effects of one- and two-stage short implant surgery on the marginal bone loss or ISQ (implant stability coefficient - resonance frequency analysis device measurement) values of the implant in diabetic patients? Participants will come for their 3rd, 6th and 12th month controls. - Participants will receive two adjacent short implants. - A randomly selected one of these short implants will undergo a one-stage implant surgery, and the other a two-stage implant surgery. - Data will be obtained through non-invasive evaluation methods during the surgery and subsequent control stages. Researchers will also test one- and two-stage short implant surgeries in a control group of healthy individuals. Thus, the effects of diabetes on these two techniques will be better understood by comparing them with the healthy control group.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 32
Est. completion date May 14, 2025
Est. primary completion date June 14, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - The maxillary and mandibular posterior region (distal part of the canine in each quadrant) must have toothless space for two adjacent short implants. - The edentulous space must have a vertical bone height of at least 5 mm. (Distance to maxillary sinus and alveolar nerve) - The edentulous space should not require horizontal bone augmentation. (for implants with diameters 3.7 - 4.1 - 4.7 - 5.3) - Bleeding on probing should be less than 10%. There should be no pathological pockets in any tooth. - Participant should not smoke more than 10 cigarettes per day. - More than 6 months must have passed since the tooth extraction from the edentulous area. - Should not have bruxism - If it is diabetes, the HbA1c value should be greater than 6.5, and if it is healthy control, the HbA1c value should be between 4 and 5. Exclusion Criteria: - Having psychological problems - Smoking more than 10 cigarettes per day - Pregnancy status if female patient - Having a medication or disease that will cause abnormal post-operative bleeding - Alcohol and drug use

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
One stage implant surgery
It is a technique in which the healing cap is connected to the implant at the stage of implant placement.
Two stage implant surgery
It is a technique in which the healing cap is connected to the implant three months after the implant is placed.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Erzincan University Mode Medical Implant Manufacturer

Outcome

Type Measure Description Time frame Safety issue
Primary One-year survival of the implant To observe whether the implant is performing its function. The implant continues to support the tooth connected to it. At the end of 12 months of follow-up from the surgery in which the implant was placed in the bone
Primary Evaluation of the status of osseointegration Fusion of the dental implant with the bone at the microscopic level. Osseointegration will be evaluated as successful or unsuccessful. Successful osseointegration is defined by no mobility in the implant, no radiolucency around the implant on radiography, and no pain in the implant. Otherwise, the osseointegration of the implant is considered unsuccessful. Three months after the implant is placed in the bone. (At the end of three months)
Secondary Implant Stability Quotient (ISQ Value) The value obtained by the resonance frequency analysis (RFA) device used to measure the primary stability of dental implants. The RFA technique is based on continual excitation of the implant through dynamic vibration analysis. A transducer is connected to an implant, which is excited over a range of sound frequencies with subsequent measurement of the vibratory oscillation of the implant. It is a non-invasive technique. 1- Surgical stage where the implant is placed; 2- Three months after the implant is placed in the bone. At the end of three months
Secondary Marginal bone level change It defines the change in the marginal bone level in the neck area of the implant. It is determined by radiographic examination. The initial radiograph is compared with the radiograph at the end of three months. In measurements where the implant platform is the reference point, bone level changes are calculated in mm. 1- Surgical stage where the implant is placed; 2- Three months after the implant is placed in the bone; 3- Six months after the implant is placed in the bone; 4- Twelve months after the implant is placed in the bone
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A